Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTS109 for Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT06770504Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of YTS-109 in autoimmune hemolytic anemia (AIHA) and Evans syndrome, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Dose Limiting Toxicity at 28 days, Treatment-Emergent Adverse Events at 12 months and 3 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
YTS-109
03
Conditions
autoimmune hemolytic anemia (AIHA)Evans syndrome
Beyond the preview
Go deeper on NCT06770504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06770504.